Company profile
VIR BIOTECHNOLOGY, INC.
NASDAQ:VIRBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (4)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ELEBSIRAN | phase3 | — | 11 | active |
| SOTROVIMAB | phase3 | — | 6 | completed, terminated |
| TOBEVIBART | phase3 | — | 8 | active |
| SONAVIBART | phase2 | — | 2 | completed, terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (21)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05567783 | phase2 | terminated | 2022-10-30 | 2023-05-05 | Vir Biotechnology, Inc. | A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A |
| NCT05612581 | phase1_2 | completed | 2023-05-10 | 2024-10-15 | Vir Biotechnology, Inc. | A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection |
| NCT06903338 | phase3 | active_not_recruiting | 2025-03-12 | 2026-12-31 | Vir Biotechnology, Inc. | A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection |
| NCT07142811 | phase2 | active_not_recruiting | 2025-08-05 | 2026-11-01 | Vir Biotechnology, Inc. | A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection |
| NCT07128550 | phase3 | active_not_recruiting | 2025-07-30 | 2026-12-01 | Vir Biotechnology, Inc. | A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide |
FDA applications (0)
No records yet.